Covered in Theory, Denied in Practice: The Growing Rift Between What Clinicians Prescribe Digitally and What Insurers Will Pay For

For millions of Americans, a conversation with a physician has begun to end differently than it once did. Instead of — or alongside — a paper prescription, patients are leaving appointments with app recommendations: a digital therapeutic for insomnia, a behavioral health platform for substance use disorder, a glucose management tool synced to a continuous monitor. The clinical rationale is sound. The evidence base, in many cases, is substantial. The insurance coverage, however, is another matter entirely.

The gap between what clinicians recommend and what insurers reimburse has always existed in some form. But the rapid proliferation of prescription digital therapeutics (PDTs) and mobile health applications has widened that gap in ways that are newly consequential — and poorly understood by patients who assume a physician's recommendation implies financial coverage.

When the Formulary Hasn't Caught Up

Traditional insurance formularies were built around pharmaceutical products: pills, injections, infusions, and devices with established billing codes. Digital health tools occupy an awkward position in this architecture. Many carry FDA clearance or authorization. Some have been validated through randomized controlled trials. Yet they arrive in a reimbursement ecosystem that was never designed to accommodate software as medicine.

The result is a patchwork of coverage decisions that varies not just by insurer, but by plan type, employer group, and state. A patient enrolled in a large commercial plan in Massachusetts may find that a clinician-recommended app for cognitive behavioral therapy for insomnia is covered. The same patient on a high-deductible plan in Tennessee may find no coverage at all — and no clear pathway to appeal.

Insurers have been slow to assign consistent billing codes to digital therapeutics, and the Current Procedural Terminology (CPT) code system maintained by the American Medical Association has only recently begun to incorporate remote therapeutic monitoring in ways that could support reimbursement. Even where codes exist, individual payer policies frequently override them.

The Hidden Cost Patients Absorb

When a physician recommends a digital tool that insurance won't cover, patients face a choice that rarely feels like a choice at all. They can pay out of pocket — subscription fees for digital therapeutics can range from $20 to more than $300 per month — or they can forgo the recommendation entirely. A third option, substituting a free consumer app, introduces its own risks: reduced clinical oversight, unvalidated algorithms, and data privacy concerns that clinical-grade platforms are typically designed to mitigate.

For patients managing chronic conditions — diabetes, hypertension, depression, opioid use disorder — the stakes of that substitution are not trivial. A patient who cannot afford a clinician-recommended digital therapeutic for alcohol use disorder and instead downloads an unvetted sobriety tracker is not receiving equivalent care. The recommendation may have looked the same. The outcomes may not be.

The financial burden also falls unevenly. Patients with higher incomes are more likely to absorb out-of-pocket costs without disrupting their care. Those on Medicaid, Medicare, or employer-sponsored plans with high cost-sharing are disproportionately affected — compounding existing disparities in access to digital health tools that mHealthSystem has documented in prior reporting on broadband inequity and underserved populations.

What Insurers Are — and Are Not — Doing

Some commercial insurers have begun to move. Cigna, UnitedHealth Group, and Blue Cross Blue Shield affiliates have each announced pilot programs or coverage expansions for select digital therapeutics, particularly in behavioral health, where demand accelerated sharply during and after the COVID-19 pandemic. Employers, who bear significant influence over the benefit designs of self-funded plans, have shown increasing willingness to add digital health tools to their offerings — often through digital health point solutions that sit outside traditional insurance architecture.

But these developments remain fragmented. There is no uniform national standard governing how digital therapeutics are evaluated for coverage, no equivalent of the pharmacy and therapeutics committee process that governs drug formularies. Each insurer conducts its own assessment, applies its own evidentiary thresholds, and sets its own reimbursement rates — when it sets them at all.

Medicare's coverage of digital health tools is particularly constrained. The program has been cautious in extending remote patient monitoring and digital therapeutic coverage, and while regulatory waivers during the public health emergency expanded telehealth access broadly, specific coverage for prescription digital therapeutics has lagged. Medicaid coverage varies by state, with some programs actively piloting digital therapeutic reimbursement and others offering no pathway whatsoever.

The Physician's Uncomfortable Position

Clinicians who recommend digital tools are often unaware of the coverage landscape their patients will encounter. A physician who prescribes a digital CBT platform for insomnia or a connected inhaler for asthma management may have reviewed the clinical evidence and determined the tool represents best practice. What that physician is unlikely to have done is verify whether the patient's specific insurance plan covers the product — a step that would require navigating payer portals and benefit summaries that are rarely accessible at the point of care.

This creates a dynamic where the recommendation is made in good clinical faith but arrives without the financial context patients need to act on it. Patients, in turn, may assume coverage exists because their physician suggested the tool, only to discover otherwise when a claim is denied or when they search for the app and find a subscription paywall.

Some health systems have begun to address this by embedding benefit verification workflows into their electronic health record systems or partnering with digital health companies that offer patient assistance programs. These efforts are meaningful but far from standard.

Toward a More Coherent Coverage Framework

Resolving the prescription-coverage paradox will require movement on several fronts simultaneously. Payers need standardized evidentiary frameworks for evaluating digital therapeutics — criteria that are transparent, consistently applied, and responsive to the pace of innovation in the field. Billing infrastructure needs to evolve to accommodate software-based interventions in the same way it accommodates durable medical equipment or specialty pharmaceuticals.

Regulatory clarity from the FDA, which has worked to define the category of prescription digital therapeutics through its Digital Health Center of Excellence, provides a foundation — but FDA authorization alone does not compel insurance coverage, a distinction that patients and clinicians alike often misunderstand.

For patients navigating this landscape today, the most practical guidance is to ask directly: before acting on a clinician's digital health recommendation, contact your insurer, confirm coverage status, and request documentation in writing if coverage is confirmed. If coverage is denied, ask your provider whether a Letter of Medical Necessity may support an appeal.

The promise of mobile health — care that is accessible, personalized, and continuously connected — is substantial. But that promise is only as meaningful as the financial systems that allow patients to actually access it. Until coverage frameworks catch up with clinical practice, the prescription paradox will continue to fall hardest on the patients who can least afford it.